← Leaderboards
Yu Leo Lei
University Of Pittsburgh At Pittsburgh
$8,848,025
Attributed
$16,745,209
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,745,209 · 8
By mechanism
R01$9,041,953 · 3
U01$6,247,852 · 2
R00$863,484 · 1
R03$338,336 · 1
K99$253,584 · 1
Top collaborators
- James J. Moon12 shared
- Nouri Neamati4 shared
- John Chadwick Brenner3 shared
- Steven Bennett Chinn3 shared
- Thomas D Wang3 shared
- Yuying Xie2 shared
- Christopher Ryan Donnelly1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHead And Neck Squamous Cell CarcinomaImmuneTumorMalignant NeoplasmsResponseHead And Neck CancerResistanceOralEngineeringImmune Checkpoint BlockadeSignal TransductionIn VivoPublic Health RelevanceImmunotherapyPathway InteractionsMediatingMalignant Mouth NeoplasmImmunitySuccessInterferonsInterferon Type IProgramsNeoplastic Cell
Grant awards (33)
Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy$674,252
U01 · FY2025 · DE · contact PI
Engineered Nano-formulations for STING Activation$654,648
R01 · FY2025 · DE
New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer$584,137
R01 · FY2025 · DE
Restoring the Immunogenicity of Head and Neck Cancer$559,720
R01 · FY2025 · DE · contact PI
Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy$675,425
U01 · FY2024 · DE · contact PI
New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer$572,454
R01 · FY2024 · DE
Engineered Nano-formulations for STING Activation$558,881
R01 · FY2024 · DE
Restoring the Immunogenicity of Head and Neck Cancer$555,467
R01 · FY2024 · DE · contact PI
Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy$689,330
U01 · FY2023 · DE · contact PI
New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer$584,137
R01 · FY2023 · DE
Engineered Nano-formulations for STING Activation$575,252
R01 · FY2023 · DE
Restoring the Immunogenicity of Head and Neck Cancer$561,890
R01 · FY2023 · DE · contact PI
New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer$578,297
R01 · FY2022 · DE
Engineered Nano-formulations for STING Activation$574,732
R01 · FY2022 · DE
Develop a Therapeutic Nano-vaccine against Head and Neck Cancer$366,795
R01 · FY2022 · DE · contact PI
Identifying non-opioid strategies to manage oral cancer pain$250,000
R01 · FY2022 · DE · contact PI
New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer$584,137
R01 · FY2021 · DE
Develop a Therapeutic Nano-vaccine against Head and Neck Cancer$370,500
R01 · FY2021 · DE · contact PI
Enhance Immunoprevention by Blocking Early Expansion of Suppressive Myeloid Cells - Supplement Proposal$250,000
U01 · FY2021 · DE · contact PI
Robust Immuno-prevention Strategies for High-Risk Oral Epithelial Dysplasia$158,870
U01 · FY2021 · DE · contact PI
Develop a Therapeutic Nano-vaccine against Head and Neck Cancer$370,500
R01 · FY2020 · DE · contact PI
Robust Immuno-prevention Strategies for High-Risk Oral Epithelial Dysplasia$3,595,405
U01 · FY2019 · DE · contact PI
Develop a Therapeutic Nano-vaccine against Head and Neck Cancer$370,500
R01 · FY2019 · DE · contact PI
Robust immunoprevention strategies for high-risk oral epithelial dysplasia$204,570
U01 · FY2019 · DE · contact PI
Development of a Prognostic Compound Immunoscore for Head and Neck Cancer$161,997
R03 · FY2019 · DE · contact PI
Develop a Therapeutic Nano-vaccine against Head and Neck Cancer$369,906
R01 · FY2018 · DE · contact PI
Autophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximab$309,777
R00 · FY2018 · DE · contact PI
Development of a Prognostic Compound Immunoscore for Head and Neck Cancer$176,339
R03 · FY2018 · DE · contact PI
Autophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximab$249,000
R00 · FY2017 · DE · contact PI
Autophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximab$55,707
R00 · FY2017 · DE · contact PI
Autophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximab$249,000
R00 · FY2016 · DE · contact PI
Autophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximab$126,792
K99 · FY2015 · DE · contact PI
Autophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximab$126,792
K99 · FY2014 · DE · contact PI